2014/01/01 by Keiichi Okano · 1 citation
Medicine · Biochemistry, Genetics and Molecular Biology · #Pancreatic and Hepatic Oncology Research #Renal and related cancers #Pancreatitis Pathology and Treatment
paper · pdf · doi:10.3748/wjg.v20.i32.11230
openalex publication_date 2014/01/01 · openalex created_date 2025/10/10 · openalex updated_date 2026/08/01
Pancreatic cancer is difficult to diagnose at an early stage and generally has a poor prognosis. Surgical resection is the only potentially curative treatment for pancreatic carcinoma. To improve the prognosis of this disease, it is essential to detect tumors at early stages, when they are resectable. The optimal approach to screening for early pancreatic neoplasia has not been established. The International Cancer of the Pancreas Screening Consortium has recently finalized several recommendations regarding the management of patients who are at an increased risk of familial pancreatic cancer. In addition, there have been notable advances in research on serum markers, tissue markers, gene signatures, and genomic targets of pancreatic cancer. To date, however, no biomarkers have been established in the clinical setting. Advancements in imaging modalities touch all aspects of the clinical management of pancreatic diseases, including the early detection of pancreatic masses, their characterization, and evaluations of tumor resectability. This article reviews strategies for screening high-risk groups, biomarkers, and current advances in imaging modalities for the early detection of resectable pancreatic cancer.